Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Evogene Schedules Third Quarter 2024 Financial Results Release

Evogene_Logo

News provided by

Evogene

07 Nov, 2024, 14:00 IST

Share this article

Share toX

Share this article

Share toX

Zoom conference call scheduled for November 21, 2024, 9:00 AM ET

REHOVOT, Israel, Nov. 7, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the third quarter of 2024, on Thursday, November 21, 2024.

Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

To join the conference, please register in advance:
https://us06web.zoom.us/webinar/register/WN_pG-Wc0JeQIifu1dmSUYOng

The entire conference will be available online on the company's website a few days after.

About Evogene:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:

  1. Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
  2. Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
  3. AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
  4. Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.

For more information, please visit: www.evogene.com.

Logo -  https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

Contact
[email protected]
Tel: +972-8-9311901

SOURCE Evogene

Modal title

Also from this source

Evogene Releases CEO Letter to Shareholders

Evogene Releases CEO Letter to Shareholders

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative AI design of small molecules...

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Evogene Ltd . (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules...

More Releases From This Source

Explore

Artificial Intelligence

Artificial Intelligence

The Latest Artificial Intelligence News

The Latest Artificial Intelligence News

Biotechnology

Biotechnology

Computer & Electronics

Computer & Electronics

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.